Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 2,791.0 | 2,809.6 | 2,537.2 | 2,595.4 | 2,448.4 | 2,146.3 | 1,868.0 | 1,809.7 |
| Revenue growth | -0.7% | 10.7% | -2.2% | 6.0% | 14.1% | 14.9% | 3.2% | -1.6% |
| Cost of goods sold | 1,260.0 | 1,260.0 | 1,212.3 | 1,186.4 | 1,145.6 | 974.5 | 871.8 | 865.3 |
| Gross profit | 1,531.1 | 1,549.6 | 1,324.9 | 1,409.0 | 1,302.8 | 1,171.8 | 996.2 | 944.4 |
| Gross margin | 54.9% | 55.2% | 52.2% | 54.3% | 53.2% | 54.6% | 53.3% | 52.2% |
| Selling, general and administrative | 863.7 | 860.1 | 743.6 | 851.8 | 797.1 | 700.0 | 563.3 | 569.0 |
| Research and development | 153.8 | 130.8 | 119.7 | 113.9 | 106.2 | 84.8 | 58.6 | 52.1 |
| EBITA | 680.0 | 729.2 | 620.2 | 593.4 | 549.0 | 500.6 | 437.8 | 385.7 |
| EBITA margin | 24.4% | 26.0% | 24.4% | 22.9% | 22.4% | 23.3% | 23.4% | 21.3% |
| Amortization of intangibles | 164.1 | 165.6 | 158.7 | 150.0 | 149.5 | 98.8 | 63.5 | 62.4 |
| EBIT | 515.9 | 563.6 | 461.6 | 443.4 | 399.5 | 401.9 | 374.3 | 323.3 |
| EBIT margin | 18.5% | 20.1% | 18.2% | 17.1% | 16.3% | 18.7% | 20.0% | 17.9% |
| Pre-tax income | 445.9 | 559.5 | 357.7 | 339.9 | 219.6 | 284.9 | 245.7 | 244.6 |
| Income taxes | 83.0 | 74.3 | 21.9 | -122.1 | 23.2 | 129.6 | 8.1 | 7.8 |
| Tax rate | 18.6% | 13.3% | 6.1% | | 10.6% | 45.5% | 3.3% | 3.2% |
| Earnings from continuing ops | 362.7 | 484.9 | 336.3 | 462.5 | 192.1 | 310.5 | 237.7 | 236.8 |
| Earnings from discontinued ops | 0.2 | 0.3 | -0.5 | -0.5 | 4.4 | -2.7 | 0.2 | 8.9 |
| Net income | 362.9 | 485.1 | 335.8 | 462.0 | 196.4 | 307.8 | 237.8 | 245.7 |
| Net margin | 13.0% | 17.3% | 13.2% | 17.8% | 8.0% | 14.3% | 12.7% | 13.6% |
| |
| Diluted EPS | $7.67 | $10.22 | $7.11 | $9.82 | $4.10 | $6.65 | $4.99 | $4.93 |
| Shares outstanding (diluted) | 47.3 | 47.4 | 47.3 | 47.1 | 46.8 | 46.7 | 47.6 | 48.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|